<p>根据 DCM Advisors LLC 最近向证券交易委员会（SEC）提交的文件，该公司在第四季度将其在 CVS Health Co.（纽约证券交易所代码：CVS - 免费报告）的持股增加了 15.5%。该基金在季度内额外购买了 10,920 股后，持有该药房运营商的 81,530 股股票。CVS Health 占 DCM Advisors LLC 持有资产的 1.6%，使其成为该公司第 21 大持仓。截至其最近向证券交易委员会（SEC）提交的文件，DCM Advisors LLC 在 CVS Health 的持股价值为 3,435,000 美元。</p>
<ul>
<li>MarketBeat 周报 – 05/12 - 05/16</li>
</ul>
<p>其他一些机构投资者和对冲基金最近也调整了对该股票的持仓。Orion Capital Management LLC 在第四季度购买了 CVS Health 的新股份，价值约 54,000 美元。McIlrath &amp; Eck LLC 在第四季度将其在 CVS Health 的持股增加了 32.6%。McIlrath &amp; Eck LLC 现在持有 707 股该药房运营商的股票，价值 32,000 美元，此前在上个季度又购买了 174 股。Novem Group 在第四季度购买了 CVS Health 的新股份，价值约 562,000 美元。NCM Capital Management LLC 在第四季度将其在 CVS Health 的持股增加了 184.2%。NCM Capital Management LLC 现在持有 11,225 股该药房运营商的股票，价值 504,000 美元，此前在上个季度又购买了 7,276 股。最后，White Knight Strategic Wealth Advisors LLC 在第四季度将其在 CVS Health 的持股增加了 176.0%。White Knight Strategic Wealth Advisors LLC 现在持有 15,740 股该药房运营商的股票，价值 707,000 美元，此前在上个季度又购买了 10,038 股。80.66% 的股票由机构投资者持有。</p>
<h2>CVS Health 的内部买卖</h2>
<p>在 CVS Health 的其他消息中，高级副总裁 James David Clark 于 3 月 5 日星期三出售了 7,513 股公司的股票。该股票以 66.35 美元的平均价格出售，总交易额为 498,487.55 美元。出售完成后，该高级副总裁现在持有 8,394 股公司股票，价值 556,941.90 美元。这笔交易代表其持仓减少了 47.23%。该出售在向 SEC 提交的文件中披露，文件可通过此超链接获取。内部人士持有公司 1.22% 的股票。</p>
<h2>分析师评级变动</h2>
<ul>
<li>现在是购买诺和诺德股票的好时机吗？</li>
</ul>
<p>一些分析师最近对该公司发布了报告。摩根士丹利在 4 月 15 日星期二的研究报告中重申了对 CVS Health 股票的 “增持” 评级。Piper Sandler 在 3 月 21 日星期五将 CVS Health 的目标价格从 72.00 美元上调至 74.00 美元，并给予该股票 “增持” 评级。瑞银集团在 5 月 2 日星期五的研究报告中将 CVS Health 的目标价格从 67.00 美元上调至 71.00 美元，并给予该股票 “中性” 评级。瑞穗在 4 月 9 日星期三的研究报告中将 CVS Health 的目标价格从 70.00 美元上调至 76.00 美元，并给予该股票 “跑赢大盘” 评级。最后，Wolfe Research 在 2 月 11 日星期二的研究报告中将 CVS Health 的目标价格从 67.00 美元上调至 70.00 美元，并给予该股票 “增持” 评级。三位投资分析师对该股票给予了持有评级，十七位分析师给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat，该股票的共识评级为 “适度买入”，共识目标价格为 74.94 美元。</p>
<p><strong>查看我们对 CVS 的最新分析</strong></p>
<h2>CVS Health 股价下跌 2.5%</h2>
<ul>
<li>在业绩疲软和 CVS-诺和诺德合作后，艾利 Lilly 值得购买吗？</li>
</ul>
<p>纽约证券交易所 CVS 周四开盘价为 62.13 美元。该公司的市值为 785.9 亿美元，市盈率为 16.97，市盈增长比率为 0.98，贝塔值为 0.60。该公司的流动比率为 0.81，速动比率为 0.60，债务与股本比率为 0.80。CVS Health Co.的 12 个月低点为 43.56 美元，12 个月高点为 72.51 美元。该股票的 50 日移动平均线为 66.41 美元，200 日移动平均线为 59.34 美元。</p>
<p>CVS Health（纽约证券交易所代码：CVS - 获取免费报告）最近于 5 月 1 日星期四发布了季度财报。该药房运营商报告季度每股收益为 2.25 美元，超出共识预期的 1.62 美元，超出幅度为 0.63 美元。CVS Health 的股本回报率为 9.11%，净利润率为 1.24%。该公司在本季度的收入为 945.9 亿美元，而共识预期为 930.7 亿美元。在去年同期，该公司发布的每股收益为 1.31 美元。该公司的季度收入较去年同期增长了 7.0%。平均而言，股票研究分析师预计 CVS Health Co.在当前财政年度将发布 5.89 美元的每股收益。</p>
<h2>CVS Health 宣布分红</h2>
<p>该公司最近还宣布了一项季度分红，该分红于 5 月 1 日星期四支付。4 月 22 日星期二的登记股东获得每股 0.665 美元的分红。这代表着每年 2.66 美元的分红和 4.28% 的收益率。该分红的除息日期为 4 月 22 日星期二。CVS Health 的分红支付比率为 63.48%。</p>
<h2>关于 CVS Health</h2>
<p>（免费报告）</p>
<p>CVS Health Corporation 在美国提供健康解决方案。它通过医疗保险、健康服务和药房及消费者健康三个部门运营。医疗保险部门提供传统、自愿和消费者导向的健康保险产品及相关服务。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过 CVS Health</li>
<li>澳大利亚证券交易所（ASX）是什么</li>
<li>300 亿美元的人工智能机会：它会推动 Meta 的下一个激增吗？</li>
<li>现在购买的三只沃伦·巴菲特股票</li>
<li>微软可能会在欧盟反垄断案件接近解决时反弹</li>
<li>专家股票交易心理技巧</li>
<li>英特尔重新聚焦：NEX 出售和铸造转型标志着新时代的开始</li>
</ul>
<p><strong>想知道其他对冲基金持有 CVS 的情况吗？</strong> 请访问 HoldingsChannel.com 获取 CVS Health Co. (NYSE:CVS - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 CVS Health 吗？</h2>
<p>在考虑 CVS Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 CVS Health 并不在名单上。</p>
<p>虽然 CVS Health 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

西维斯

<p>DCM Advisors LLC 在第四季度将其在 CVS Health Co. (NYSE:CVS) 的持股增加了 15.5%，额外购买了 10,920 股，总持股达到 81,530 股，价值 340 万美元。其他机构投资者也调整了他们的持股。内部交易方面，副总裁 James David Clark 出售了 7,513 股。分析师对 CVS Health 的一致评级为 “适度买入”，目标价格为 74.94 美元。CVS Health 报告第一季度每股收益为 2.25 美元，超出预期，市值为 785.9 亿美元</p>

<p>DCM Advisors LLC grew its stake in CVS Health Co. (NYSE:CVS - Free Report) by 15.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 81,530 shares of the pharmacy operator's stock after acquiring an additional 10,920 shares during the quarter. CVS Health accounts for 1.6% of DCM Advisors LLC's holdings, making the stock its 21st biggest position. DCM Advisors LLC's holdings in CVS Health were worth $3,435,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>根据 DCM Advisors LLC 最近向证券交易委员会（SEC）提交的文件，该公司在第四季度将其在 CVS Health Co.（纽约证券交易所代码：CVS - 免费报告）的持股增加了 15.5%。该基金在季度内额外购买了 10,920 股后，持有该药房运营商的 81,530 股股票。CVS Health 占 DCM Advisors LLC 持有资产的 1.6%，使其成为该公司第 21 大持仓。截至其最近向证券交易委员会（SEC）提交的文件，DCM Advisors LLC 在 CVS Health 的持股价值为 3,435,000 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 05/12 - 05/16</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 05/12 - 05/16</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Orion Capital Management LLC bought a new stake in CVS Health during the 4th quarter worth approximately $54,000. McIlrath &amp; Eck LLC increased its stake in CVS Health by 32.6% during the 4th quarter. McIlrath &amp; Eck LLC now owns 707 shares of the pharmacy operator's stock worth $32,000 after purchasing an additional 174 shares in the last quarter. Novem Group bought a new stake in CVS Health during the 4th quarter worth approximately $562,000. NCM Capital Management LLC increased its stake in CVS Health by 184.2% during the 4th quarter. NCM Capital Management LLC now owns 11,225 shares of the pharmacy operator's stock worth $504,000 after purchasing an additional 7,276 shares in the last quarter. Finally, White Knight Strategic Wealth Advisors LLC increased its stake in CVS Health by 176.0% during the 4th quarter. White Knight Strategic Wealth Advisors LLC now owns 15,740 shares of the pharmacy operator's stock worth $707,000 after purchasing an additional 10,038 shares in the last quarter. 80.66% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也调整了对该股票的持仓。Orion Capital Management LLC 在第四季度购买了 CVS Health 的新股份，价值约 54,000 美元。McIlrath &amp; Eck LLC 在第四季度将其在 CVS Health 的持股增加了 32.6%。McIlrath &amp; Eck LLC 现在持有 707 股该药房运营商的股票，价值 32,000 美元，此前在上个季度又购买了 174 股。Novem Group 在第四季度购买了 CVS Health 的新股份，价值约 562,000 美元。NCM Capital Management LLC 在第四季度将其在 CVS Health 的持股增加了 184.2%。NCM Capital Management LLC 现在持有 11,225 股该药房运营商的股票，价值 504,000 美元，此前在上个季度又购买了 7,276 股。最后，White Knight Strategic Wealth Advisors LLC 在第四季度将其在 CVS Health 的持股增加了 176.0%。White Knight Strategic Wealth Advisors LLC 现在持有 15,740 股该药房运营商的股票，价值 707,000 美元，此前在上个季度又购买了 10,038 股。80.66% 的股票由机构投资者持有。</p>
</div><h2>Insider Buying and Selling at CVS Health</h2>
<div class="lb-trans"><h2>CVS Health 的内部买卖</h2>
</div><p>In other CVS Health news, SVP James David Clark sold 7,513 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares of the company's stock, valued at $556,941.90. This trade represents a 47.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.22% of the company's stock.</p>
<div class="lb-trans"><p>在 CVS Health 的其他消息中，高级副总裁 James David Clark 于 3 月 5 日星期三出售了 7,513 股公司的股票。该股票以 66.35 美元的平均价格出售，总交易额为 498,487.55 美元。出售完成后，该高级副总裁现在持有 8,394 股公司股票，价值 556,941.90 美元。这笔交易代表其持仓减少了 47.23%。该出售在向 SEC 提交的文件中披露，文件可通过此超链接获取。内部人士持有公司 1.22% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>Is It Time to Buy the Dip in Novo Nordisk Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>现在是购买诺和诺德股票的好时机吗？</li>
</ul>
</div><p>A number of analysts recently issued reports on the company. Morgan Stanley reissued an &#34;overweight&#34; rating on shares of CVS Health in a research note on Tuesday, April 15th. Piper Sandler increased their target price on CVS Health from $72.00 to $74.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, March 21st. UBS Group upped their price target on CVS Health from $67.00 to $71.00 and gave the stock a &#34;neutral&#34; rating in a research report on Friday, May 2nd. Mizuho upped their price target on CVS Health from $70.00 to $76.00 and gave the stock an &#34;outperform&#34; rating in a research report on Wednesday, April 9th. Finally, Wolfe Research upped their price target on CVS Health from 67.00 to 70.00 and gave the stock an &#34;overweight&#34; rating in a research report on Tuesday, February 11th. Three investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $74.94.</p>
<div class="lb-trans"><p>一些分析师最近对该公司发布了报告。摩根士丹利在 4 月 15 日星期二的研究报告中重申了对 CVS Health 股票的 “增持” 评级。Piper Sandler 在 3 月 21 日星期五将 CVS Health 的目标价格从 72.00 美元上调至 74.00 美元，并给予该股票 “增持” 评级。瑞银集团在 5 月 2 日星期五的研究报告中将 CVS Health 的目标价格从 67.00 美元上调至 71.00 美元，并给予该股票 “中性” 评级。瑞穗在 4 月 9 日星期三的研究报告中将 CVS Health 的目标价格从 70.00 美元上调至 76.00 美元，并给予该股票 “跑赢大盘” 评级。最后，Wolfe Research 在 2 月 11 日星期二的研究报告中将 CVS Health 的目标价格从 67.00 美元上调至 70.00 美元，并给予该股票 “增持” 评级。三位投资分析师对该股票给予了持有评级，十七位分析师给予了买入评级，一位分析师给予了强烈买入评级。根据 MarketBeat，该股票的共识评级为 “适度买入”，共识目标价格为 74.94 美元。</p>
</div><p><strong>View Our Latest Analysis on CVS</strong></p>
<div class="lb-trans"><p><strong>查看我们对 CVS 的最新分析</strong></p>
</div><h2>CVS Health Trading Down 2.5%</h2>
<div class="lb-trans"><h2>CVS Health 股价下跌 2.5%</h2>
</div><ul>
<li>Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?</li>
</ul>
<div class="lb-trans"><ul>
<li>在业绩疲软和 CVS-诺和诺德合作后，艾利 Lilly 值得购买吗？</li>
</ul>
</div><p>NYSE CVS opened at $62.13 on Thursday. The company has a market cap of $78.59 billion, a PE ratio of 16.97, a PEG ratio of 0.98 and a beta of 0.60. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80. CVS Health Co. has a 12 month low of $43.56 and a 12 month high of $72.51. The stock has a 50 day moving average of $66.41 and a 200-day moving average of $59.34.</p>
<div class="lb-trans"><p>纽约证券交易所 CVS 周四开盘价为 62.13 美元。该公司的市值为 785.9 亿美元，市盈率为 16.97，市盈增长比率为 0.98，贝塔值为 0.60。该公司的流动比率为 0.81，速动比率为 0.60，债务与股本比率为 0.80。CVS Health Co.的 12 个月低点为 43.56 美元，12 个月高点为 72.51 美元。该股票的 50 日移动平均线为 66.41 美元，200 日移动平均线为 59.34 美元。</p>
</div><p>CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating the consensus estimate of $1.62 by $0.63. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The company had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. During the same quarter in the prior year, the firm posted $1.31 EPS. The firm's revenue for the quarter was up 7.0% compared to the same quarter last year. On average, equities research analysts anticipate that CVS Health Co. will post 5.89 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>CVS Health（纽约证券交易所代码：CVS - 获取免费报告）最近于 5 月 1 日星期四发布了季度财报。该药房运营商报告季度每股收益为 2.25 美元，超出共识预期的 1.62 美元，超出幅度为 0.63 美元。CVS Health 的股本回报率为 9.11%，净利润率为 1.24%。该公司在本季度的收入为 945.9 亿美元，而共识预期为 930.7 亿美元。在去年同期，该公司发布的每股收益为 1.31 美元。该公司的季度收入较去年同期增长了 7.0%。平均而言，股票研究分析师预计 CVS Health Co.在当前财政年度将发布 5.89 美元的每股收益。</p>
</div><h2>CVS Health Announces Dividend</h2>
<div class="lb-trans"><h2>CVS Health 宣布分红</h2>
</div><p>The firm also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd were issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a yield of 4.28%. The ex-dividend date of this dividend was Tuesday, April 22nd. CVS Health's dividend payout ratio is 63.48%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，该分红于 5 月 1 日星期四支付。4 月 22 日星期二的登记股东获得每股 0.665 美元的分红。这代表着每年 2.66 美元的分红和 4.28% 的收益率。该分红的除息日期为 4 月 22 日星期二。CVS Health 的分红支付比率为 63.48%。</p>
</div><h2>About CVS Health</h2>
<div class="lb-trans"><h2>关于 CVS Health</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy &amp; Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.</p>
<div class="lb-trans"><p>CVS Health Corporation 在美国提供健康解决方案。它通过医疗保险、健康服务和药房及消费者健康三个部门运营。医疗保险部门提供传统、自愿和消费者导向的健康保险产品及相关服务。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than CVS Health</li>
<li>What is the Australian Securities Exchange (ASX)</li>
<li>$30B AI Opportunity: Will It Power Meta’s Next Surge?</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>Microsoft Could Rally as EU Antitrust Case Nears Resolution</li>
<li>Expert Stock Trading Psychology Tips</li>
<li>Intel Refocuses: NEX Sale and Foundry Pivot Signal New Era</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 CVS Health</li>
<li>澳大利亚证券交易所（ASX）是什么</li>
<li>300 亿美元的人工智能机会：它会推动 Meta 的下一个激增吗？</li>
<li>现在购买的三只沃伦·巴菲特股票</li>
<li>微软可能会在欧盟反垄断案件接近解决时反弹</li>
<li>专家股票交易心理技巧</li>
<li>英特尔重新聚焦：NEX 出售和铸造转型标志着新时代的开始</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding CVS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVS - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对冲基金持有 CVS 的情况吗？</strong> 请访问 HoldingsChannel.com 获取 CVS Health Co. (NYSE:CVS - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=CVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in CVS Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 CVS Health 吗？</h2>
</div><p>Before you consider CVS Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CVS Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 CVS Health 并不在名单上。</p>
</div><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 CVS Health 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

DCM Advisors LLC 购买了 10,920 股西维斯（CVS Health Co.，纽约证券交易所代码：CVS）的股票